Social Anxiety DisordertaVNSNCT07772401
Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)Therapy for Social Anxiety Disorder
A study testing taVNS in people with Social Anxiety Disorder and Social Fear, run by Second Affiliated Hospital, Zhejiang University, School of Medicine at 2 sites in China.
Trial summary
This clinical trial aims to evaluate the efficacy and safety of transcutaneous auricular vagus nerve stimulation (taVNS) in patients with social anxiety disorder (SAD). The study addresses the following key research questions: Does taVNS demonstrate preliminary clinical efficacy in the treatment of SAD? What adverse… Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Social Anxiety Disorder, Social Fear
- What is being tested?
- taVNS
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 50 participants
- Where
- 2 sitesChina
- Study dates
- 5 Sep 2025to 1 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Fulfillment of the DSM-5 diagnostic criteria for Social Anxiety Disorder (SAD). A Liebowitz Social Anxiety Scale (LSAS) score of ≥30 and a Clinical Global Social Phobia Inventory score greater than 30 Age between 18 and 70 years. Voluntary provision of written informed consent.
Who cannot join
- A lifetime history of bipolar disorder, schizophrenia, or obsessive-compulsive disorder.
- Any cognitive impairments that could interfere with the study. Significant suicidal ideation or behavior within the past six months. Patients with rapidly deteriorating conditions. Previous taVNS treatment within the past month. Contraindications to auricular vagus nerve stimulation, such as ear infections, inflammation, skin lesions, or hypersensitivity of the ear.
- Presence of a pacemaker or other implanted medical devices, or severe neurological, renal, cardiovascular, or hepatic diseases.
- Concurrent engagement in any form of psychotherapy. History of psychotropic medications or alcohol abuse. Inability to comply with psychological assessments. Incapable of providing informed consent. Pregnant or lactating. Other reasons as deemed unsuitable for inclusion by the research team.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
China2 sites, 2 recruiting
- Not yet recruiting
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, 311500
Bin Gao, 18768188021, zjugaobin@163.com
- Recruiting
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, 311500
Bin Gao Bin Gao, 17799859423, 1096248474@qq.com
About this study
Official title: Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)for Social Anxiety Disorder: A Randomized Controlled Clinical Trial.
This clinical trial aims to evaluate the efficacy and safety of transcutaneous auricular vagus nerve stimulation (taVNS) in patients with social anxiety disorder (SAD). The study addresses the following key research questions:
- Does taVNS demonstrate preliminary clinical efficacy in the treatment of SAD?
- What adverse events may occur during taVNS treatment, and what is the treatment compliance of the subjects?
Read the detailed description
Social Anxiety Disorder (SAD) is a common psychiatric condition characterized by excessive fear of social situations, leading to significant functional impairment and reduced quality of life. Conventional treatments, including pharmacotherapy and cognitive behavioral therapy, have limitations in terms of response rate and adverse effects. Transcutaneous auricular vagus nerve stimulation (taVNS) is a novel, non-invasive neuromodulation approach targeting the auricular branch of the vagus nerve, which has shown potential anxiolytic effects in clinical studies.
This clinical trial is designed to evaluate the efficacy and safety of taVNS in patients with SAD. The trial adopts a randomized, doubled-blind, sham-controlled design. Participants will be allocated to receive either active taVNS or sham stimulation using identical devices. Active taVNS will deliver bilateral electrical stimulation at the concha cymba and concha cavum with a current intensity up to the individual's maximum tolerable level (≤5 mA), whereas sham stimulation will use a weak current intensity of 0.1 mA.
The primary objectives of this pilot study are to determine whether taVNS demonstrates preliminary clinical efficacy in improving social anxiety symptoms and to assess the incidence of adverse events during treatment. The findings will provide critical data to guide future large-scale randomized controlled trials evaluating the therapeutic potential of taVNS in SAD.
- Conditions
- Social Anxiety Disorder, Social Fear
- Being tested
- taVNS, sham-taVNS
- Keywords
- vagus nerve stimulation, social anxiety disorder
- Medical subject headings
- Phobia, Social
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
taVNSDevice
The study will employ the transcutaneous auricular vagus nerve stimulation (taVNS) stimulator for therapeutic intervention. Electrical stimulation was administered at bilateral cymba conchae (kidney auricular point, CO10) and cavum conchae (heart auricular point, CO15). The stimulation parameters were as follows: frequency of 20 Hz, pulse width <1 ms, with current intensity adjusted to the patient's maximum tolerance level while being maintained below 5 mA. The intervention protocol consisted of two 30-minute stimulation sessions per day for 8 consecutive weeks.
sham-taVNSDevice
The study will employ the sham transcutaneous auricular vagus nerve stimulation (sham-taVNS) for this intervention. Electrical stimulation will be administered at bilateral cymba conchae (kidney auricular point, CO10) and cavum conchae (heart auricular point, CO15). The stimulation parameters were as follows: frequency of 20 Hz, pulse width <1 ms, and current intensity of 0.1 mA. The intervention protocol consisted of two 30-minute stimulation sessions per day for 8 consecutive weeks.
| Study group | Role | What they receive |
|---|---|---|
| taVNS group | Experimental | Arm Description:
Participants in this group will receive transcutaneous auricular vagus nerve stimulation (taVNS) using the TVNS-100 stimulator, with stimulation intensity adjusted to the maximum tolerable level (≤5 mA) for 8 weeks.
Assigned Interventions:
Device: taVNS The study will employ the taVNS for therapeutic intervention. Electrical stimulation will be administered at bilateral cymba conchae (kidney auricular point, CO10) and cavum conchae (heart auricular point, CO15). The stimulation parameters will be: frequency of 20 Hz, pulse width <1 ms, with current intensity adjusted to the patient's maximum tolerance level while being maintained below 5 mA. The intervention protocol consists of two 30-minute stimulation sessions per day for 8 consecutive weeks. Receives: Device: taVNS |
| sham-taVNS group | Sham comparator | Arm Description:
Participants in this group will receive sham stimulation using the same device, delivering a weak current (0.1 mA) intended to mimic taVNS without therapeutic effect, for 8 weeks.
Assigned Interventions:
Device: sham transcutaneous auricular vagus nerve stimulation (sham-taVNS) The study will employ the sham taVNS for this intervention. Electrical stimulation will be administered at bilateral cymba conchae (kidney auricular point, CO10) and cavum conchae (heart auricular point, CO15). The stimulation parameters will be: frequency of 20 Hz, pulse width <1 ms, and current intensity of 0.1 mA. The intervention protocol consists of two 30-minute stimulation sessions per day for 8 consecutive weeks. Receives: Device: sham-taVNS |
What is being measured
The primary outcome is the main question the study is designed to answer.
LSAS (Liebowitz Social Anxiety Scale)
The outcome measure is the percentage reduction rate of the Liebowitz Social Anxiety Scale (LSAS) total score (unit: %, measurement tool: Liebowitz Social Anxiety Scale, a 24-item self-report questionnaire). The LSAS is a 24-item scale with a minimum total score of 0 and a maximum total score of 144; higher scores indicate more severe social anxiety symptoms (i.e., a worse outcome). The primary outcome was the change in LSAS total score, with core efficacy evaluated based on the difference in total scores between baseline and the 8-week intervention period. The LSAS score reduction rate (%) was calculated as [(Pre-treatment total score - Post-treatment total score) / Pre-treatment total score] × 100%.
Measured: Assessments will be conducted at baseline, weeks 2, 4, and 8 of the intervention, and at week 12 during follow-up.
Secondary outcomes (10)
HAMA (Hamilton Anxiety Rating Scale.)
The outcome measure is the total score of the Hamilton Anxiety Rating Scale (HAMA) (measurement tool: Hamilton Anxiety Rating Scale, a 14-item clinician-rated scale; unit: total score). The HAMA is a 14-item scale with a minimum total score of 0 and a maximum total score of 56; higher scores indicate more severe anxiety symptoms (i.e., a worse outcome).
Measured: Baseline and weeks 2, 4, 8 of intervention, plus 12-week follow-up.
Hamilton Depression Rating Scale (HAMD)
The outcome measure is the total score of the Hamilton Depression Rating Scale (HAMD) (measurement tool: Hamilton Depression Rating Scale, a 17-item clinician-rated scale; unit: total score). The HAMD is a 17-item scale with a minimum total score of 0 and a maximum total score of 52; higher scores indicate more severe depressive symptoms (i.e., a worse outcome).
Measured: baseline, week2, week4, week8, week12
Adherence to the intervention
Intervention completion times or rates will be used for the evaluation.
Measured: Assessment wii be conducted at baseline, and at weeks 2, 4, and 8 of the intervention.
Rate of adherence to the intervention
Adherence will be defined as the percentage of prescribed stimulation sessions completed by each participant during the 8-week intervention period. A rate of 100% indicates that all scheduled sessions were completed as instructed.
Measured: Adherence will be assessed weekly during the 8-week intervention.
Social Interaction Anxiety Scale (SIAS)
The outcome measure is the total score of the Social Interaction Anxiety Scale (SIAS) (measurement tool: Social Interaction Anxiety Scale, a 20-item self-rated scale; unit: total score). The SIAS is a 20-item scale with a minimum total score of 0 and a maximum total score of 80; higher scores indicate more severe social interaction anxiety symptoms (i.e., a worse outcome).
Measured: Baseline and weeks 2, 4, 8 of intervention, plus 12-week follow-up.
SAS (Social Adaptation Self-evaluation Scale)
The outcome measure is the total score of the Social Adaptation Self-evaluation Scale (SAS) (measurement tool: Social Adaptation Self-evaluation Scale, a 21-item self-rated scale; unit: total score). The SAS is a 21-item scale with a minimum total score of 0 and a maximum total score of 63; higher scores indicate poorer social adaptation status (i.e., a worse outcome).
Measured: Baseline and weeks 2, 4, 8 of intervention, plus 12-week follow-up.
BFNE (Brief Fear of Negative Evaluation Scale)
The outcome measure is the total score of the Brief Fear of Negative Evaluation Scale (BFNE) (measurement tool: Brief Fear of Negative Evaluation Scale, a 12-item self-rated scale; unit: total score). The BFNE is a 12-item scale with a minimum total score of 12 and a maximum total score of 60; higher scores indicate more severe fear of negative evaluation (i.e., a worse outcome).
Measured: Baseline and weeks 2, 4, 8 of intervention, plus 12-week follow-up.
Pittsburgh Sleep Quality Index (PSQI)
The outcome measure is the total score of the Pittsburgh Sleep Quality Index (PSQI) (measurement tool: Pittsburgh Sleep Quality Index, a 19-item self-rated scale; unit: total score). The PSQI is a 19-item scale with a minimum total score of 0 and a maximum total score of 21; higher scores indicate poorer overall sleep quality (i.e., a worse outcome).
Measured: Baseline and weeks 2, 4, 8 of intervention, plus 12-week follow-up.
HRV (Heart Rate Variability)
The outcome measure is the heart rate variability (HRV) (measurement tool: standardized electrocardiographic monitoring system; unit: millisecond). HRV reflects the autonomic nervous system regulatory function; lower HRV values indicate poorer cardiac autonomic regulation and higher physiological stress levels (i.e., a worse outcome).
Measured: Baseline and weeks 8 of intervention.
blood IL-6, IL-10, CRP, cortisol
The outcome measure is the serum level of Interleukin-6 (IL-6), Interleukin-10 (IL-10), cortisol, C-reactive Protein (CRP)(measurement tool: enzyme-linked immunosorbent assay (ELISA); ).
Measured: Baseline and weeks 8 of intervention.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Aug 2026
- Study start5 Sep 2025
- Primary completion31 Aug 2026
- Study completion1 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Social Anxiety DisorderStudies of the same condition, open and under way.
- More trials run by Second Affiliated Hospital, Zhejiang University, School of MedicineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Han Xu, Principal investigator, The Second Affiliated Hospital Zhejiang University of medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07772401
- Sponsor's protocol ID
- 2025-0620
- Acronym
- taVNS
- Status last verified
- Apr 2026
- First submitted
- 22 Jul 2025
- Last updated
- 19 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)for Social Anxiety Disorder: A Randomized Controlled Clinical Trial.
- ClinicalTrials.gov ID
- NCT07772401
- Acronym / sponsor ID
- taVNS / 2025-0620
- Conditions
- Social Anxiety Disorder, Social Fear
- Keywords
- vagus nerve stimulation, social anxiety disorder
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of MedicineUniversity, hospital or other
- Study start
- 5 Sep 2025 (actual)
- Primary completion
- 31 Aug 2026 (actual)
- Study completion
- 1 Dec 2026 (estimated)
- First posted
- 19 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This clinical trial aims to evaluate the efficacy and safety of transcutaneous auricular vagus nerve stimulation (taVNS) in patients with social anxiety disorder (SAD). The study addresses the following key research questions:
- Does taVNS demonstrate preliminary clinical efficacy in the treatment of SAD?
- What adverse events may occur during taVNS treatment, and what is the treatment compliance of the subjects?
Detailed description
Social Anxiety Disorder (SAD) is a common psychiatric condition characterized by excessive fear of social situations, leading to significant functional impairment and reduced quality of life. Conventional treatments, including pharmacotherapy and cognitive behavioral therapy, have limitations in terms of response rate and adverse effects. Transcutaneous auricular vagus nerve stimulation (taVNS) is a novel, non-invasive neuromodulation approach targeting the auricular branch of the vagus nerve, which has shown potential anxiolytic effects in clinical studies.
This clinical trial is designed to evaluate the efficacy and safety of taVNS in patients with SAD. The trial adopts a randomized, doubled-blind, sham-controlled design. Participants will be allocated to receive either active taVNS or sham stimulation using identical devices. Active taVNS will deliver bilateral electrical stimulation at the concha cymba and concha cavum with a current intensity up to the individual's maximum tolerable level (≤5 mA), whereas sham stimulation will use a weak current intensity of 0.1 mA.
The primary objectives of this pilot study are to determine whether taVNS demonstrates preliminary clinical efficacy in improving social anxiety symptoms and to assess the incidence of adverse events during treatment. The findings will provide critical data to guide future large-scale randomized controlled trials evaluating the therapeutic potential of taVNS in SAD.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| taVNS group | Experimental | Device: taVNSArm Description: Participants in this group will receive transcutaneous auricular vagus nerve stimulation (taVNS) using the TVNS-100 stimulator, with stimulation intensity adjusted to the maximum tolerable level (≤5 mA) for 8 weeks. Assigned Interventions: Device: taVNS The study will employ the taVNS for therapeutic intervention. Electrical stimulation will be administered at bilateral cymba conchae (kidney auricular point, CO10) and cavum conchae (heart auricular point, CO15). The stimulation parameters will be: frequency of 20 Hz, pulse width <1 ms, with current intensity adjusted to the patient's maximum tolerance level while being maintained below 5 mA. The intervention protocol consists of two 30-minute stimulation sessions per day for 8 consecutive weeks. |
| sham-taVNS group | Sham comparator | Device: sham-taVNSArm Description: Participants in this group will receive sham stimulation using the same device, delivering a weak current (0.1 mA) intended to mimic taVNS without therapeutic effect, for 8 weeks. Assigned Interventions: Device: sham transcutaneous auricular vagus nerve stimulation (sham-taVNS) The study will employ the sham taVNS for this intervention. Electrical stimulation will be administered at bilateral cymba conchae (kidney auricular point, CO10) and cavum conchae (heart auricular point, CO15). The stimulation parameters will be: frequency of 20 Hz, pulse width <1 ms, and current intensity of 0.1 mA. The intervention protocol consists of two 30-minute stimulation sessions per day for 8 consecutive weeks. |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Fulfillment of the DSM-5 diagnostic criteria for Social Anxiety Disorder (SAD). A Liebowitz Social Anxiety Scale (LSAS) score of ≥30 and a Clinical Global Social Phobia Inventory score greater than 30 Age between 18 and 70 years. Voluntary provision of written informed consent.
Key exclusion criteria (4 listed)
- A lifetime history of bipolar disorder, schizophrenia, or obsessive-compulsive disorder.
- Any cognitive impairments that could interfere with the study. Significant suicidal ideation or behavior within the past six months. Patients with rapidly deteriorating conditions. Previous taVNS treatment within the past month. Contraindications to auricular vagus nerve stimulation, such as ear infections, inflammation, skin lesions, or hypersensitivity of the ear.
- Presence of a pacemaker or other implanted medical devices, or severe neurological, renal, cardiovascular, or hepatic diseases.
- Concurrent engagement in any form of psychotherapy. History of psychotropic medications or alcohol abuse. Inability to comply with psychological assessments. Incapable of providing informed consent. Pregnant or lactating. Other reasons as deemed unsuitable for inclusion by the research team.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| taVNSThe study will employ the transcutaneous auricular vagus nerve stimulation (taVNS) stimulator for therapeutic intervention. Electrical stimulation was administered at bilateral cymba conchae (kidney auricular point, CO10) and cavum conchae (heart auricular point, CO15). The stimulation parameters were as follows: frequency of 20 Hz, pulse width <1 ms, with current intensity adjusted to the patient's maximum tolerance level while being maintained below 5 mA. The intervention protocol consisted of two 30-minute stimulation sessions per day for 8 consecutive weeks. | Device | taVNS group |
| sham-taVNSThe study will employ the sham transcutaneous auricular vagus nerve stimulation (sham-taVNS) for this intervention. Electrical stimulation will be administered at bilateral cymba conchae (kidney auricular point, CO10) and cavum conchae (heart auricular point, CO15). The stimulation parameters were as follows: frequency of 20 Hz, pulse width <1 ms, and current intensity of 0.1 mA. The intervention protocol consisted of two 30-minute stimulation sessions per day for 8 consecutive weeks. | Device | sham-taVNS group |
Primary outcome
LSAS (Liebowitz Social Anxiety Scale)
Time frame: Assessments will be conducted at baseline, weeks 2, 4, and 8 of the intervention, and at week 12 during follow-up.
The outcome measure is the percentage reduction rate of the Liebowitz Social Anxiety Scale (LSAS) total score (unit: %, measurement tool: Liebowitz Social Anxiety Scale, a 24-item self-report questionnaire). The LSAS is a 24-item scale with a minimum total score of 0 and a maximum total score of 144; higher scores indicate more severe social anxiety symptoms (i.e., a worse outcome). The primary outcome was the change in LSAS total score, with core efficacy evaluated based on the difference in total scores between baseline and the 8-week intervention period. The LSAS score reduction rate (%) was calculated as [(Pre-treatment total score - Post-treatment total score) / Pre-treatment total score] × 100%.
10 secondary outcomes
HAMA (Hamilton Anxiety Rating Scale.)
Time frame: Baseline and weeks 2, 4, 8 of intervention, plus 12-week follow-up.
Hamilton Depression Rating Scale (HAMD)
Time frame: baseline, week2, week4, week8, week12
Adherence to the intervention
Time frame: Assessment wii be conducted at baseline, and at weeks 2, 4, and 8 of the intervention.
Rate of adherence to the intervention
Time frame: Adherence will be assessed weekly during the 8-week intervention.
Social Interaction Anxiety Scale (SIAS)
Time frame: Baseline and weeks 2, 4, 8 of intervention, plus 12-week follow-up.
SAS (Social Adaptation Self-evaluation Scale)
Time frame: Baseline and weeks 2, 4, 8 of intervention, plus 12-week follow-up.
BFNE (Brief Fear of Negative Evaluation Scale)
Time frame: Baseline and weeks 2, 4, 8 of intervention, plus 12-week follow-up.
Pittsburgh Sleep Quality Index (PSQI)
Time frame: Baseline and weeks 2, 4, 8 of intervention, plus 12-week follow-up.
HRV (Heart Rate Variability)
Time frame: Baseline and weeks 8 of intervention.
blood IL-6, IL-10, CRP, cortisol
Time frame: Baseline and weeks 8 of intervention.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Oct 2026.
Related trials for Social Anxiety Disorder
Not yet recruiting
Preventive and Personalized Digital Emotion Regulation Skills Intervention to Reduce Depression and Anxiety in Youths With Adverse Childhood Experiences
Adverse Childhood Experience, Depression / Major Depressive Disorder
Recruiting
Bonding Before Birth: A mHealth Intervention for First-time Expectant Couples
Anxiety, Pregnancy
Recruiting
Comprehensive Assessment of Rehabilitation Experience Using the SAFE Scale
Caregiver Anxiety, Acquired Brain Injury
Not yet recruiting
Online Study on the Impact of a Self-Help Tool for Social Anxiety
Social Anxiety
Active, not recruiting
Targeting Social Function in Anxiety and Eating Disorders
Eating Disorders, Anorexia Nervosa
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Han Xu principal investigator
The Second Affiliated Hospital Zhejiang University of medicine
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing taVNS in people with Social Anxiety Disorder and Social Fear, run by Second Affiliated Hospital, Zhejiang University, School of Medicine at 2 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 19 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Bin Gao (+8618768188021, zjugaobin@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
LSAS (Liebowitz Social Anxiety Scale) (time frame: Assessments will be conducted at baseline, weeks 2, 4, and 8 of the intervention, and at week 12 during follow-up.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Oct 2026; AzTrials last refreshed its copy on 7 Nov 2026.